Clinical Trial Update: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for low dose naltrexone in metastatic melanoma, castration-resistant prostate cancer, and renal cancer; study terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Prostate Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Low Dose Naltrexone (naltrexone)

Snippet

Sponsor: Brown University | Conditions: Melanoma, Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-07-27